Researchers have developed a urine test that can screen for tumor DNA and detect whether a patient has residual bladder cancer after undergoing surgery to remove the tumor. This test may also determine whether immunotherapy treatment administered after surgery has been effective or if residual bladder cancer remains. The development, reported by BioMedWire, represents a significant advancement in non-invasive cancer monitoring.
Bladder cancer is one of the most common cancers worldwide, with high recurrence rates even after surgical removal of the primary tumor. Current surveillance methods include cystoscopy and imaging, which are invasive, costly, and may not detect microscopic residual disease. The new urine-based liquid biopsy offers a simpler, less invasive alternative. By analyzing circulating tumor DNA (ctDNA) in urine, the test can identify the presence of cancer cells with high sensitivity and specificity.
The test's ability to predict response to immunotherapy is particularly noteworthy. Immunotherapy has emerged as a powerful treatment for bladder cancer, but not all patients respond. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are developing novel immunotherapies that could benefit from such a predictive tool. Identifying non-responders early could spare them from ineffective treatments and enable alternative strategies.
According to the press release, the test is based on detecting tumor-specific genetic alterations in urine samples. This approach leverages the fact that bladder tumors shed DNA directly into the urinary tract, making urine a rich source of cancer biomarkers. The research team validated the test in a cohort of patients, showing that it could accurately distinguish between those with residual cancer and those without.
If widely adopted, this test could transform bladder cancer management. It could reduce the need for frequent cystoscopies, lower healthcare costs, and improve patient quality of life. Moreover, real-time monitoring of treatment response could enable adaptive therapy, where regimens are adjusted based on molecular evidence of disease activity.
The implications extend beyond bladder cancer. Similar urine-based tests could be developed for other urological malignancies, such as prostate or kidney cancer. The success of this approach underscores the growing role of liquid biopsies in oncology, providing a window into tumor dynamics without invasive procedures.
As research progresses, validation in larger multicenter trials will be crucial. The developers aim to refine the test's sensitivity and specificity, potentially integrating it into standard clinical guidelines. For now, the test represents a promising step toward precision medicine for bladder cancer patients.
For more information, visit BioMedWire for full terms and disclaimers.
